Advanced Filters
noise

Spandau, Germany Clinical Trials

A listing of Spandau, Germany clinical trials actively recruiting patients volunteers.

Found 423 clinical trials
M Miriam Rösner

Effects of Bloodletting Acupuncture for Subacute and Chronic Non-specific Low Back Pain

Evaluation of a bloodletting acupuncture at the fossa poplitea in comparison to bloodletting acupuncture at the regio glutaea and a waiting list control group in patients with subacute and chronic non-specific pain low back pain.

18 - 65 years of age All Phase N/A
L Lindsey Otten, Dr.

Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs)

The goal of this post-market study is to describe the effect of a liquid supplement containing 2 specific human milk oligosaccharides (HMOs), 2'-fucosyllactose [2'FL] and lacto-N-neotetraose [LNnT], on feeding tolerance, growth, and adverse events of special interest in preterm infants in a real-world setting.

- 14 years of age All Phase N/A
B Boehringer Ingelheim

A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated

The trial aims to study the safety, tolerability, and pharmacokinetics of single and multiple rising doses of BI 3776528.

18 - 50 years of age Male Phase 1

Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

Finding biomarkers for stopping bulevirtide treatment of patients with hepatitis delta

18 years of age All Phase N/A
M Martin Wermke, MD

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR …

18 years of age All Phase 1
K Kerem Böge, Dr.

OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia

The effectiveness of current treatment options for sociocognitive deficits and negative symptoms (NS) in schizophrenia spectrum disorders (SSD) remains limited. The cause of NS is thought to be an interference between the mesocorticolimbic dopamine system for social reward expectancy and the network for socioemotional processes. Oxytocin (OXT) may enhance functional …

18 - 75 years of age All Phase N/A
S Sebastian Stintzing, MD

A Clinical Study of Arfolitixorin in Patients With mCRC

This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 60 people will participate in the study. There is already a standard therapy for treatment of colorectal cancer. …

18 years of age All Phase 1/2
D Dr. Valeria Rios Rodriguez

ToFAcitinib in Early Active Axial SpondyloarThritis:

This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axSpA and inadequate response to at least …

18 - 45 years of age All Phase 4
B Boehringer Ingelheim

A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male subjects following administration of multiple rising doses.

18 - 50 years of age Male Phase 1

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).

18 years of age All Phase 1/2

Simplify language using AI